Skip to main content

Table 3 Multivariate analyses

From: Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial

Factor

HR (95% CI) (p value to exclude from model)

Model 1* (all pts)

Model 2* (all pts)

Model 3* (all pts)

Model 4* (all pts)

Fixed variables

    

Age (years)

1.01 (0.99, 1.02)

1.01 (1.00, 1.02)

1.01 (1.00, 1.02)

1.00 (0.98, 1.02)

 Tumour grade

    

  III

1

1

1

1

  IV

1.84 (1.10, 3.08)

2.25 (1.33, 3.83)

2.43 (1.48, 3.98)

1.53 (0.81, 2.92)

 WHO Performance status

    

  0

1

1

1

1

  1

0.86 (0.58, 1.27)

0.93 (0.63, 1.39)

0.93 (0.63, 1.38)

0.79 (0.51, 1.21)

  2

1.42 (0.93, 2.17)

1.63 (1.06, 2.53)

1.62 (1.05, 2.50)

1.39 (0.87, 2.22)

  3

1.23 (0.69, 2.20)

1.54 (0.85, 2.81)

1.46 (0.93, 2.97)

1.64 (0.88, 3.06)

 Gender

    

  Male

1

1

1

1

  Female

0.80 (0.59, 1.07)

0.82 (0.61, 1.10)

0.80 (0.57, 1.03)

0.91 (0.66, 1.25)

 Additional independent factors

    

 IDH1

    

 Normal

1

1

 

1

 Mutated

0.45 (0.29, 0.67) (p < 0.001)

0.58 (0.37, 0.91) (p = 0.015)

 

0.32 (0.18, 0.56) (P < 0.001)

 PTEN

    

 Normal

  

1

 

 Hemizygous deletion

  

1.83 (1.29, 2.61)

 

 Homozygous deletion

  

1.47 (0.68, 3.16) P = 0.003

 

 MGMT methylation

    

 <10%

 

1

1

1

 ≥10%

 

0.59 (0.42, 0.82) P = 0.002

0.49 (0.36, 0.67) (p < 0.001)

0.44 (0.30, 0.63) (p = 0.002)

  1. *Model 1: mutation data only, final backwards stepwise selection model.
  2. Model 2: addition of MGMT methylation status to Model 1.
  3. Model 3: final backwards stepwise model including mutation data and MGMT methylation status.
  4. Model 4: final backwards stepwise model including mutation data and MGMT methylation status, MGMT hemizygous deletion patients only.
Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us